Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Abstract 3321: Real-world clinical outcome analyses in head and neck squamous cell carcinoma (HNSCC) to uncover TIGIT biology in patients treated with first-line immune checkpoint inhibitors

Meghna Das Thakur, Xiaoyong Fu, Shahed Iqbal, Joon Rhee

Cancer Res (2025) 85 (8_Supplement_1): 3321.

https://doi.org/10.1158/1538-7445.AM2025-3321

Published: 21 April 2025

View articletitled, Abstract 3321: Real-world clinical outcome analyses in head and neck squamous cell carcinoma (HNSCC) to uncover TIGIT biology in patients treated with first-line immune checkpoint inhibitors

Journal Articles

Abstract 6459: Molecular profiling of advanced non-small cell lung cancer in response to first-line immune checkpoint inhibitors and/or chemotherapy using multimodal real-world data

Xiaoyong Fu, Jordan Kardos, Paola Correa, Min Wang, Li, Jackson Egen, Shahed Iqbal

Cancer Res (2024) 84 (6_Supplement): 6459.

https://doi.org/10.1158/1538-7445.AM2024-6459

Published: 22 March 2024

View articletitled, Abstract 6459: Molecular profiling of advanced non-small cell lung cancer in response to first-line immune checkpoint inhibitors and/or chemotherapy using multimodal real-world data

Journal Articles

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Sarmistha Nanda, Martin J. Shea, Rachel Schiff, C. Kent Osborne, Mothaffar Rimawi, Xiaoyong Fu

Cancer Res (2023) 83 (5_Supplement): P2-03-10.

https://doi.org/10.1158/1538-7445.SABCS22-P2-03-10

Published: 01 March 2023

View articletitled, Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Journal Articles

Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Fu-Tien Liao, Tia Gordon, Chia Chia Liu, Pier Selenica, Yingjie Zhu, Juber Patel, Sarmistha Nanda, Lanfang Qin, Xiaoyong Fu, Andrea Gazzo, Antonio Marra, Juan Blanco-Heredia, Britta Weigelt, Jorge Reis-Filho, C. Kent Osborne, Mothaffar Rimawi, Rachel Schiff, Jamunarani Veeraraghavan

Cancer Res (2023) 83 (5_Supplement): P1-13-17.

https://doi.org/10.1158/1538-7445.SABCS22-P1-13-17

Published: 01 March 2023

View articletitled, Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Journal Articles

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Chia Chia Liu, Lanfang Qin, Shanunak Sathe, Sarmistha Nanda, Jamunarani Veeraraghavan, Ofir Cohen, Nikhil Wagle, Mothaffar Rimawi, C. Kent Osborne, Xiaoyong Fu, Rachel Schiff

Cancer Res (2023) 83 (5_Supplement): PD10-03.

https://doi.org/10.1158/1538-7445.SABCS22-PD10-03

Published: 01 March 2023

View articletitled, Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

Journal Articles

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Cancer Res (2022) 82 (20): 3673–3686.

https://doi.org/10.1158/0008-5472.CAN-21-3186

Published: 17 October 2022

View articletitled, A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Includes: Supplementary data

Journal Articles

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Chia Chia Liu, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Resel Pereira, Martin J. Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Zhijie Liu, Mothaffar F. Rimawi, C. Kent Osborne, Rachel Schiff, Xiaoyong Fu

Cancer Res (2022) 82 (4_Supplement): PD1-05.

https://doi.org/10.1158/1538-7445.SABCS21-PD1-05

Published: 15 February 2022

View articletitled, Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Journal Articles

Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Hariprasad Thangavel, Yingmin Zhu, Kurt R. Christensen, Xiaoyong Fu, Dean Edwards, Rachel Schiff, Meghana V. Trivedi

Cancer Res (2021) 81 (13_Supplement): 930.

https://doi.org/10.1158/1538-7445.AM2021-930

Published: 01 July 2021

View articletitled, Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Journal Articles

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Vidyalakshmi Sethunath, Xiaoyong Fu, Pamela L Luna, Sarmistha Nanda, Martin Shea, Jamunarani Veeraraghavan, Carmine De Angelis, Huizhong Hu, Chad Shaw, Mothaffar Rimawi, C. Kent Osborne, Rachel Schiff

Cancer Res (2021) 81 (4_Supplement): PS5-29.

https://doi.org/10.1158/1538-7445.SABCS20-PS5-29

Published: 15 February 2021

View articletitled, Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Journal Articles

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Xiaoyong Fu, Resel Pereira, Lanfang Qin, Carmine De Angelis, Sarmistha Nanda, Martin Shea, Agostina Nardone, Rinath Jeselsohn, Ofir Cohen, Nikhil Wagle, Mothaffar Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2021) 81 (4_Supplement): PD8-03.

https://doi.org/10.1158/1538-7445.SABCS20-PD8-03

Published: 15 February 2021

View articletitled, Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Journal Articles

Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Jennifer Torres, Hariprasad Thangavel, Xiaoyong Fu, Rachel Schiff, Meghana V. Trivedi

Cancer Res (2020) 80 (16_Supplement): 3508.

https://doi.org/10.1158/1538-7445.AM2020-3508

Published: 15 August 2020

View articletitled, Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Journal Articles

Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer

Xiaoyong Fu, Resel Pereira, Carmine De Angelis, Sarmistha Nanda, Lanfang Qin, Jamunarani Veeraraghavan, Pier Selenica, Britta Weigelt, Jorge S Reis-Filho, Agostina Nardone, Rinath Jeselsohn, Myles Brown, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): PD7-01.

https://doi.org/10.1158/1538-7445.SABCS19-PD7-01

Published: 15 February 2020

View articletitled, Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer

Journal Articles

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Cancer Res (2020) 80 (4_Supplement): GS2-01.

https://doi.org/10.1158/1538-7445.SABCS19-GS2-01

Published: 15 February 2020

View articletitled, Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Journal Articles

Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Carmine De Angelis, Maria Letizia Cataldo, Agostina Nardone, Jamunarani Veeraraghavan, Xiaoyong Fu, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Resel Pereira, Britta Weigelt, Jorge S. Reis-Filho, Mothaffar F. Rimawi, Rinath Jeselsohn, Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): PD2-02.

https://doi.org/10.1158/1538-7445.SABCS19-PD2-02

Published: 15 February 2020

View articletitled, Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Journal Articles

Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer

Xiaoyong Fu, Resel Pereira, Carmine De Angelis, Sarmistha Nanda, Lanfang Qin, Martin J Shea, Tamika Mitchell, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carolina Gutierrez, Balázs Győrffy, Ofir Cohen, Nikhil Wagle, Agostina Nardone, Rinath Jeselsohn, Myles Brown, Mothaffar F Rimawi, C Kent Osborne, Rachel Schiff

Cancer Res (2020) 80 (4_Supplement): P6-04-02.

https://doi.org/10.1158/1538-7445.SABCS19-P6-04-02

Published: 15 February 2020

View articletitled, Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer

Journal Articles

Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies

Rachel Schiff, Jamunarani Veeraraghavan, Xiaoyong Fu

Cancer Res (2018) 78 (13_Supplement): SY01-01.

https://doi.org/10.1158/1538-7445.AM2018-SY01-01

Published: 01 July 2018

View articletitled, Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies

Journal Articles

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Cancer Res (2018) 78 (3): 671–684.

https://doi.org/10.1158/0008-5472.CAN-17-1327

Published: 31 January 2018

View articletitled, Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Includes: Supplementary data

Journal Articles

Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models

Agostina Nardone, Amit Goldstein, Martin J. Shea, Tamika Mithchell, Xiaoyong Fu, Carmine De Angelis, Huizhong Hu, Xiaowei Xu, Mahitha Rajendran, Mark O'Connor, Gershon Locker, Susan Hilsenbeck, Kent Osborne, Rachel Schiff

Cancer Res (2015) 75 (15_Supplement): LB-166.

https://doi.org/10.1158/1538-7445.AM2015-LB-166

Published: 01 August 2015

View articletitled, Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models

Journal Articles

Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination

Agostina Nardone, Gladys Morrison, Xiaoyong Fu, Martin Shea, Tamika Mitchell, Teresa Klinowska, C Kent Osborne, Rachel Schiff

Cancer Res (2015) 75 (9_Supplement): P3-05-03.

https://doi.org/10.1158/1538-7445.SABCS14-P3-05-03

Published: 01 May 2015

View articletitled, Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination

Journal Articles

Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells

Cancer Res (2015) 75 (9_Supplement): P3-05-13.

https://doi.org/10.1158/1538-7445.SABCS14-P3-05-13

Published: 01 May 2015

View articletitled, Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 3321: Real-world clinical outcome analyses in head and neck squamous cell carcinoma (HNSCC) to uncover TIGIT biology in patients treated with first-line immune checkpoint inhibitors

Abstract 6459: Molecular profiling of advanced non-small cell lung cancer in response to first-line immune checkpoint inhibitors and/or chemotherapy using multimodal real-world data

Abstract P2-03-10: DNA replication licensing is associated with resistance to CDK4/6 inhibitors in ER-positive breast cancer

Abstract P1-13-17: Hyperactivation of the EGFR pathway is associated with resistance to tucatinib in HER2-positive breast cancer models

Abstract PD10-03: PD10-03 Super-enhancer-oriented integrative bioinformatics identifies aberrant KLF4 signaling in endocrine-resistant breast cancer (BC)

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer

Abstract 930: Production of functionally active recombinant FOXA1: The first step towards targeted drug discovery

Abstract PS5-29: Insights into the molecular underpinnings of the mevalonate pathway-YAP/TAZ-driven anti-HER2 therapy resistance in HER2+ breast cancer (BC)

Abstract PD8-03: A FOXA1/FRA1-centered transcriptional axis regulates interferon signaling in high FOXA1-associated endocrine-resistant and metastatic breast cancer

Abstract 3508: FOXA1 genetic alterations in whites versus blacks or African Americans in breast and prostate cancer

Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer

Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract PD2-02: Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer

Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer

Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models

Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination

Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only